Tuesday , August 20 2019
Home / argentina / A group of scientists believe that they hold the key to the definitive treatment of cancer

A group of scientists believe that they hold the key to the definitive treatment of cancer




Cancer is one of the biggest causes of death in the world. According to data from the World Health Organization (WHO), 1 in 5 men and 1 in 6 women currently occur, and 9.6 million people died in 2018 after the illness.

However, there are several treatments that try to eradicate cancer, but until now there is no one definitely ending with this condition.

Recently it was reported that a group of Israeli scientists from the pharmaceutical lab Accelerated evolutionary biotechnology (AEBi) can change the prospect that we have for cancer because, as they announced, they are very close to determining a much more effective treatment than current ones to determine the disease.

"We believe that we will offer a complete cancer medicine for a year," he said. Dan Aridor, president of AEB.

"It will be effective from the first day, it will take weeks and will have minimal or no side effects, much less than most other treatments on the market," he added.

According to The Jerusalem Post, this treatment known as "MuTaTo" (multi-purpose toxin) is an antibiotic product of a combination of toxins that specifically attack cancer cells and eliminate the possibility that the disease may recur. .

For his part Ilan Morad, the research leader, told an Israeli channel that experts will be responsible for analyzing the type of cancer of each patient in order to provide an antibiotic designed specifically to treat their disease.

That is to say, although it is intended to create a general remedy, cancer treatment through "MuTaTo" will be specially designed for each person, analyzing the samples from each biopsy.

Morad compared the "MuTaTo" concept to the triple drug that helped shift AIDS from the automatic death penalty to chronic illness.

But, unlike HIV and AIDS, where patients must take medication in perpetuity, with "MuTaTo" cells will be killed, so treatment can be stopped in just a few weeks.

As expected, this announcement generated all kinds of reactions, and there are those who take these statements with skepticism, pointing out that the study is limited and there is no scientific publication to support it.

One of them is Len Liechtenfeld, director of the American Cancer Society, who says it's too early to conclude that the drug will work successfully in humans, because so far only experiences with mice have occurred.

"Unfortunately, we must be aware that this is far from effective treatment for people with cancer and much less cure," he wrote in his personal blog.


Source link